Korsana is a speculative biotech with below-floor quality (2.5), a 43% drawdown from its high and only 12.9% upside against 15.0% downside, partly offset by narrowing losses, accumulation and positive analyst sentiment.
Thesis pillars
- Quality Below Minimum Floor—
- Binary Biotech Deep Drawdown—
- Narrowing Losses Earnings Beats—
- +2 more pillars — see the Why tab for full reasoning
Korsana Biosciences, Inc. (KRSA) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $31.66: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: Below-average business quality.
Korsana Biosciences, formerly Cyclerion Therapeutics, is a preclinical-stage biopharma company focused on neuropsychiatric disorders, led by CYC-126, an individualized anesthetic-based therapy for treatment-resistant depression in-licensed from MIT. It has no approved products... Read more
Sell if holding. Engine safety override at $31.66: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: Below-average business quality. Chart setup: RSI 49 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Korsana Biosciences, Inc.
About Korsana Biosciences, Inc.
Korsana Biosciences, formerly Cyclerion Therapeutics, reported a net loss of $3.5 million for 2025 and unrestricted cash of approximately $3.2 million at December 31, 2025, with management citing substantial doubt about its ability to continue as a going concern. Its lead program, CYC-126, an anesthetic-based therapy for treatment-resistant depression, was in-licensed from MIT in September 2025, and the company targets a Phase 2 start in Australia in the second half of 2026.
The company has no approved products and has never generated product revenue. CYC-126 combines two generic intravenous anesthetics, propofol and dexmedetomidine, with a personalized delivery system that monitors brain activity, and the treatment is expected to take place in a hospital setting. Treatment-resistant depression affects an estimated 2.8 to 3 million adults in the United States. Income comes from legacy soluble guanylate cyclase assets: praliciguat is licensed to Akebia, which paid a $3.0 million upfront fee in 2021, $1.75 million in amendment payments and a $1.0 million milestone in February 2026, with eligibility for up to approximately $557.5 million in further milestones plus royalties from mid-single digits to 20%. Zagociguat and CY3018 were sold to Tisento in July 2023 for $8.0 million in cash plus about 10% of Tisento Parent equity, and a non-compete with Tisento runs through July 2028. The MIT license carries up to $4.4 million in milestones, and the Medsteer collaboration up to $3.7 million.
Show full overview
Funding is the sharpest lens on this filing. Management stated that existing cash would not cover operating expenses through mid-2026, and the shelf registration is capped at one-third of non-affiliate market value because that value is under $75 million. In September 2026, the company disclosed via Form 8-K that it closed a merger with private Korsana Biosciences, Inc. and changed its name from Cyclerion Therapeutics, which could alter the program mix and share count described in the earlier 10-K.
From Korsana Biosciences, Inc.'s most recent 10-K filing, extracted October 11, 2026.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- MEDIUMpipelinelead product candidate for treatment resistant depression10-K Item 1A: 'Our business depends heavily on the successful development, clinical testing, regulatory approvals and commercialization of our lead product candidate for treatment resistant depression'
- MEDIUMcounterpartyAkebia praliciguat out-license10-K Item 1A: 'Akebia may not be successful in developing and commercializing any therapies through its praliciguat out-license with the Company.'
- LOWcounterpartyequity interest in Tisento10-K Item 1A: 'There is uncertainty as to any liquidity or monetizable value of our equity interest in Tisento, a privately-held company'
Material Events(8-K, last 90d)
- 2026-09-11Item 2.01HIGHCyclerion (renamed Korsana Biosciences, Inc.) completed its merger with private Korsana Biosciences on Sept 8, 2026 under an April 1, 2026 merger agreement, after a reverse stock split. Remaining terms truncated in provided text.SEC filing →
- 2026-09-11Item 5.01HIGHItem 5.01 (changes in control) listed with the Sept 8, 2026 merger closing; control details are not in the provided excerpt. Registrant renamed Korsana Biosciences, Inc., formerly Cyclerion Therapeutics, Inc.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $31.66: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: Below-average business quality. Chart setup: RSI 49 mid-range, Bollinger mid-band. Prior stop was $29.44. Score 5.8/10, moderate confidence.
Take-profit target: $38.28 (+20.9% upside). Prior stop was $29.44. Stop-loss: $29.44.
Quality below floor (2.5 < 4.0).
Korsana Biosciences, Inc. trades at a P/E of N/A (forward -8.9). TrendMatrix value score: 7.5/10. Verdict: Sell.
What does Korsana Biosciences, Inc. do?Korsana Biosciences, formerly Cyclerion Therapeutics, is a preclinical-stage biopharma company focused on...
Korsana Biosciences, formerly Cyclerion Therapeutics, is a preclinical-stage biopharma company focused on neuropsychiatric disorders, led by CYC-126, an individualized anesthetic-based therapy for treatment-resistant depression in-licensed from MIT. It has no approved products and earns limited income from legacy sGC stimulator assets, including praliciguat licensed to Akebia and assets sold to Tisento. Management cites substantial doubt about its ability to continue as a going concern.